Flexcin International, Inc. Charges in with New Product and Website Designed to Promote Better Joint Health for Horses-FlexEquine
All Natural, USA-made FlexEquine’s new site showcases a user-friendly format for customers.
Fort Myers, Florida (PRWEB) December 30, 2013
Flexcin International, Inc., the makers of all-natural health products for adults and pets announces it latest product, FlexEquine, for horses. FlexEquine utilizes the same human-grade ingredients found in the adult version Flexcin. The primary component, Cetyl Myristoleate (CM8®), works to lubricate the joints and muscles and reduce inflammation throughout the horses’ body. This combination of ingredients in FlexEquine with CM8® is specially designed to nourish the joints, support stronger cartilage, help to stimulate the lubricating fluid in the joints, and increase total mobility. This formulation is unique and cannot be found in any other product on the market. The new website gives customers a more user friendly site with enhanced features and additional product options.
Although joint therapy has been primarily targeted at thoroughbred and quarter horses, there are even miniature horses that deal with the same sorts of problems. Many horses are diagnosed with arthritis in their younger years, many develop the progressive problem over time; of course, this means senior horses are likely to have arthritis in one form or another, be it severe or mild. FlexEquine delivers improved joint function, increased energy, enhanced mobility and perked up demeanor, and healthy and strong joints with no side effectsAbout Flexcin International.
Flexcin International, Inc. is a manufacturer and marketer of leading natural supplements that promote optimal joint health. Along with its FlexPet line of pet joint supplements, Flexcin products are the only degenerative joint relief supplements with the CM8® ingredient to stimulate joint fluid lubrication, strengthen cartilage and increase overall mobility.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/12/prweb11452246.htm